Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry A Gusterson

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancer|February 25, 2003
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia, Susan Murray, Karen Price, et al.
Anticancer Research|January 18, 2003
LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situArmine Baltayan, Wesley Y Naritoku, Benjapom Chaiwun, et al.
Journal of Cellular Physiology|May 28, 2005
Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary glandJoanna S Morris, Torsten Stein, Marie-Anne Pringle, et al.
Development (Cambridge, England)|September 6, 2017
The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesisKelly J Soady, Giusy Tornillo, Howard Kendrick, et al.
Breast Cancer Research : BCR|February 26, 2004
Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3Torsten Stein, Joanna S Morris, Claire R Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerMarco Colleoni, Bernard F Cole, Giuseppe Viale, et al.
Oncogene|February 22, 2002
Concomitant inactivation of p53 and Chk2 in breast cancerAlexandra Sullivan, Martin Yuille, Claire Repellin, et al.
Disease Models & Mechanisms|March 15, 2014
RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary glandLaura McDonald, Nicola Ferrari, Anne Terry, et al.
The American Journal of Pathology|September 18, 2010
Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosisTorsten Stein, Emilio Cosimo, Xinzi Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancerTorsten Stein, Karen N Price, Joanna S Morris, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer|February 25, 2003
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia, Susan Murray, Karen Price, et al.
Anticancer Research|January 18, 2003
LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situArmine Baltayan, Wesley Y Naritoku, Benjapom Chaiwun, et al.
Journal of Cellular Physiology|May 28, 2005
Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary glandJoanna S Morris, Torsten Stein, Marie-Anne Pringle, et al.
Development (Cambridge, England)|September 6, 2017
The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesisKelly J Soady, Giusy Tornillo, Howard Kendrick, et al.
Breast Cancer Research : BCR|February 26, 2004
Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3Torsten Stein, Joanna S Morris, Claire R Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerMarco Colleoni, Bernard F Cole, Giuseppe Viale, et al.
Oncogene|February 22, 2002
Concomitant inactivation of p53 and Chk2 in breast cancerAlexandra Sullivan, Martin Yuille, Claire Repellin, et al.
Disease Models & Mechanisms|March 15, 2014
RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary glandLaura McDonald, Nicola Ferrari, Anne Terry, et al.
The American Journal of Pathology|September 18, 2010
Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosisTorsten Stein, Emilio Cosimo, Xinzi Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancerTorsten Stein, Karen N Price, Joanna S Morris, et al.
Pageof 3